Drug Price Transparency

The California Office of Statewide Health Planning and Development recently released the nation’s first mandatory data on wholesale acquisition cost increases for prescription drugs.
A recent report from UnitedHealth comparing specialty drug spending in hospitals and independent physician offices fails to account for critical differences between these two settings while also ignoring the chief culprit in the growth in drug spending – the drug companies themselves. 
The House Energy and Commerce Committee today approved legislation to address surprise medical bills and Medicaid disproportionate share hospital cuts.
A federal judge yesterday struck down a Centers for Medicare & Medicaid Services final rule requiring drug companies to include list prices in direct-to-consumer television advertisements of products for which Medicare and Medicaid reimbursement is available.
The White House June 24 released an executive order on “improving price and quality transparency in American health care.” The executive order focuses on five policies:
The House Energy and Commerce Subcommittee on Health today held a hearing on seven bills aimed at improving transparency in the drug supply chain to lower prices.
The Centers for Medicare & Medicaid Services May 16 released a final rule with the intent of lowering drug prices for beneficiaries enrolled in Medicare Advantage and Part D programs.
The largest U.S. pharmaceutical and biotech companies spend just 22 cents out of every dollar on research and development, according to an analysis released today by the Campaign for Sustainable Rx Pricing.
A recent Health Affairs blog post (April 19) on hospital price transparency argues that chargemaster data can be confusing to consumers. We agree, and have encouraged the Department of Health and Human Services (HHS) to focus, instead, on the information that really matters to patients – expected…
The House Ways and Means Committee today approved the Prescription Drug Sunshine, Transparency, Accountability and Reporting Act (H.R. 2113), AHA-supported legislation that would increase transparency with regard to prescription drug pricing.